In a phase 4 trial, dupilumab effectively reduces airway inflammation and mucus plugging, improving lung function and asthma control in patients with moderate to severe type 2 asthma.

Baseline factors that positively impacted clinical remission odds on dupilumab included ... levels in a moderate to severe asthma cohort, according to a poster presented here.

Dupilumab significantly reduced airway inflammation in patients with uncontrolled, moderate-to-severe type 2 asthma. Read now.

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch ...

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal ...

In a pre-specified exploratory analysis, dupilumab-treated patients who also had asthma demonstrated significant improvements in asthma control. "There is growing recognition that patients ...

The most common adverse events in the dupilumab group (occurring in at least three patients) included peripheral edema, arthralgia, back pain, blurred vision, hypertension, asthma, conjunctivitis ...